Yangjie Huang1, Ning Zhao1, Yung-Hua Wang1, Charles Truillet2, Junnian Wei1, Matthew F L Parker1, Joseph E Blecha1, Christopher R Drake3, Henry F VanBrocklin1,4, Diego Garrido-Ruiz5, Matthew P Jacobson5, Rahul Aggarwal4,6, Spencer C Behr1, Robert R Flavell1,4, David M Wilson1, Youngho Seo1,4, Michael J Evans7,4,5. 1. Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California. 2. Imagerie Moleculaire in Vivo, INSERM, CEA, Université Paris Sud, CNRS, Universite Paris Saclay, CEA-Service Hospitalier Frederic Joliot, Orsay, France. 3. Sofie Biosciences, Culver City, California. 4. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. 5. Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California; and. 6. Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, California. 7. Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California michael.evans@ucsf.edu.
Abstract
Noninvasive methods to study glucocorticoid receptor (GR) signaling are urgently needed to elaborate the complexity of GR signaling in normal physiology and human disorders, as well as to identify selective GR modulators to treat diseases. Here, we report evidence supporting translational studies with (±)-11C-5-(4-fluorobenzyl)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]-quinoline ((±)-11C-YJH08), a radioligand for PET that engages the ligand binding domain on GR. Methods: (±)-11C-YJH08 was synthesized by reacting the phenol precursor with 11C-methyl iodide. The biodistribution was studied in vivo. Specific binding was tested in vivo with adrenalectomy and ligand competition. A library of analogs was synthesized and studied in vitro and in vivo to understand the (±)-11C-YJH08 structure-activity relationship. Rodent dosimetry studies were performed to estimate the human-equivalent doses of (±)-11C-YJH08. Results: (±)-11C-YJH08 was synthesized by reaction of the phenolic precursor with 11C-methyl iodide, giving a radiochemical yield of 51.7% ± 4.7% (decay-corrected to starting 11C-methyl iodide). Specific binding was observed in many tissues, including the brain. An analysis of the (±)-YJH08 structure-activity relationship showed that (R)- and (S)-enantiomers are equally avid for GR by occupying discrete binding modes. A focused chemical screen revealed that the aryl fluoride motif on YJH08 is essential for high-affinity GR binding in vitro, high tissue uptake in vivo, and efficient passage across the blood-brain barrier. Lastly, we performed dosimetry studies on rodents, from which we estimated the human-equivalent doses of (±)-11C-YJH08 to be commensurate with the widely used 11C and 18F tracers. Conclusion: These studies reveal the molecular determinants of a high-affinity and high-selectivity ligand-receptor interaction and support the use of (±)-11C-YJH08 PET to make the first measurements of GR expression in human subjects.
Noninvasive methods to study glucocorticoid receptor (GR) signaling are urgently needed to elaborate the complexity of GR signaling in normal physiology and human disorders, as well as to identify selective GR modulators to treat diseases. Here, we report evidence supporting translational studies with (±)-11C-5-(4-fluorobenzyl)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]-quinoline ((±)-11C-YJH08), a radioligand for PET that engages the ligand binding domain on GR. Methods: (±)-11C-YJH08 was synthesized by reacting the phenol precursor with 11C-methyl iodide. The biodistribution was studied in vivo. Specific binding was tested in vivo with adrenalectomy and ligand competition. A library of analogs was synthesized and studied in vitro and in vivo to understand the (±)-11C-YJH08 structure-activity relationship. Rodent dosimetry studies were performed to estimate the human-equivalent doses of (±)-11C-YJH08. Results: (±)-11C-YJH08 was synthesized by reaction of the phenolic precursor with 11C-methyl iodide, giving a radiochemical yield of 51.7% ± 4.7% (decay-corrected to starting 11C-methyl iodide). Specific binding was observed in many tissues, including the brain. An analysis of the (±)-YJH08 structure-activity relationship showed that (R)- and (S)-enantiomers are equally avid for GR by occupying discrete binding modes. A focused chemical screen revealed that the aryl fluoride motif on YJH08 is essential for high-affinity GR binding in vitro, high tissue uptake in vivo, and efficient passage across the blood-brain barrier. Lastly, we performed dosimetry studies on rodents, from which we estimated the human-equivalent doses of (±)-11C-YJH08 to be commensurate with the widely used 11C and 18F tracers. Conclusion: These studies reveal the molecular determinants of a high-affinity and high-selectivity ligand-receptor interaction and support the use of (±)-11C-YJH08 PET to make the first measurements of GR expression in human subjects.
Authors: Noora M Scheinin; Tuula K Tolvanen; Ian A Wilson; Eveliina M Arponen; Kjell A Någren; Juha O Rinne Journal: J Nucl Med Date: 2007-01 Impact factor: 10.057
Authors: Graeme J O'Keefe; Timothy H Saunder; Steven Ng; Uwe Ackerman; Henri J Tochon-Danguy; J Gordon Chan; Sylvia Gong; Thomas Dyrks; Stefanie Lindemann; Gerhard Holl; Ludger Dinkelborg; Victor Villemagne; Christopher C Rowe Journal: J Nucl Med Date: 2009-01-21 Impact factor: 10.057
Authors: Dana E Rathkopf; Michael J Morris; Josef J Fox; Daniel C Danila; Susan F Slovin; Jeffrey H Hager; Peter J Rix; Edna Chow Maneval; Isan Chen; Mithat Gönen; Martin Fleisher; Steven M Larson; Charles L Sawyers; Howard I Scher Journal: J Clin Oncol Date: 2013-09-03 Impact factor: 44.544
Authors: Brenda F Kurland; Lanell M Peterson; Jean H Lee; Erin K Schubert; Erin R Currin; Jeanne M Link; Kenneth A Krohn; David A Mankoff; Hannah M Linden Journal: Clin Cancer Res Date: 2016-06-24 Impact factor: 12.531
Authors: Yangjie Huang; Ning Zhao; Yung-Hua Wang; Charles Truillet; Junnian Wei; Joseph E Blecha; Henry F VanBrocklin; Youngho Seo; Mohd Sayeed; Brian J Feldman; Rahul Aggarwal; Spencer C Behr; Hao Shao; David M Wilson; Javier E Villanueva-Meyer; Jason E Gestwicki; Michael J Evans Journal: ACS Chem Biol Date: 2020-04-15 Impact factor: 4.634